Loading...
XSTO
DPHA
, Last price  
SEK
Name

Guard Therapeutics International AB (publ)

Chart & performance

D1W1MN
XSTO:DPHA chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-35.15%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
28,7321,250,000715,00033,00000000000000
Net income
-109m
L+13.31%
-964,989-2,095,000-5,164,000-6,164,000-32,415,000-52,079,000-67,643,000-86,708,000-46,028,000-40,291,000-82,160,000-110,756,000-113,323,000-96,066,000-108,851,000
CFO
-109m
L+15.41%
-1,448,000-2,826,000-6,866,000-29,564,000-46,981,000-66,011,000-58,458,000-60,209,000-37,962,000-77,590,000-102,139,000-116,046,000-94,751,000-109,350,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.

Key people

Tobias Larsson Agervald
Chief Executive Officer · since 2019
Gunnar Telhammar
Chief Financial Officer · since 2019
Fredrik Werner
Interim Chief Financial Officer · since 2019
Magnus Gram
Chief Scientific Officer · since 2019
Fredrik Lehmann
Advisor in CMC (Chemistry Manufacturing and Controls) · since 2019
Ronny Renfurm
Head of Clinical Development · since 2019
Goran Forsberg
Director · since 2019
URL
https://guardtherapeutics.com/
IPO date
Apr 03, 2013
Employees
12
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Box 5216
Stockholm 102 45
SE
Previous name
A1M Pharma AB
Previous name
Preelumina AB

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT